Trial Profile
Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy Using Rifaximin.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 26 Sep 2013
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary) ; Lactulose
- Indications Liver cirrhosis
- Focus Therapeutic Use
- 20 Sep 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 08 May 2013 New trial record